How do you manage endocrine therapy for a perimenopausal woman with ER+ breast CA?

In lower risk patients to whom I would not routinely give chemotherapy - stage I-IIA, with a low or low-intermediate risk Oncotype score - I start tamoxifen and switch to an aromatase inhibitor (except in very low risk patients in whom the benefit of switching would be negligible) when they are clin...